AF
SPRY icon

Allworth Financial’s ARS Pharmaceuticals SPRY Stock Holding History

Allworth Financial’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.61K Hold
825
– – ﹤0.01% 3978
2026
Q1 		$6.63K Buy
825
+82
+11% +$786 ﹤0.01% 3783
2025
Q4 		$8.66K Sell
743
-53
-7% -$515 ﹤0.01% 3369
2025
Q3 		$8K Buy
796
+44
+6% +$631 ﹤0.01% 3277
2025
Q2 		$13.1K Buy
752
+9
+1% +$130 ﹤0.01% 2763
2025
Q1 		$10.9K Hold
743
– – ﹤0.01% 2389
2024
Q4 		$10.1K Hold
743
– – ﹤0.01% 2432
2024
Q3 		$10.8K Buy
743
+661
+806% +$7.86K ﹤0.01% 2221
2024
Q2 		$865 Hold
82
– – ﹤0.01% 3214
2024
Q1 		$839 Buy
+82
New +$611 ﹤0.01% 3137

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Allworth Financial's SPRY Position: Q2 2026 in Review

Allworth Financial held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 825 shares worth $6.61K. The position accounts for ﹤0.01% of the portfolio, ranked #3978.

Allworth Financial first reported a position in SPRY in Q1 2024 and has held it in 10 quarters since. The position peaked at $13.1K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Allworth Financial held 825 shares of ARS Pharmaceuticals worth $6.61K as of Q2 2026.
  • Allworth Financial left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3978 holding.
  • Allworth Financial first reported a position in ARS Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Allworth Financial's ARS Pharmaceuticals position peaked at $13.1K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.